when we were speaking with Vincent DeVita about the issue of oncology clinical trials, he commented that if he were starting the research that confirmed the efficacy of MOPP today, he would not be able to undertake the critical trials. Obviously, we are not advocating a position in which any researcher can undertake any clinical trial that they wish. But, perhaps it should be possible that with sufficient and robust preclinical data, and with critical safety data for the compounds, clinical trials in which a combination therapy is the starting point should be a possibility. This would also avoid the situation where phase III trials are initiated because previous trials did not include additional relevant combination arms as comparators, an approach that would not only save time and unnecessary patient accural but also money.
An obvious hurdle-in addition to the complexity of clinical trial design and recruitment-is the man-made barrier of the restrictions imposed by regulators. For example, most institutional review boards will not approve a trial concept or initiation unless the study has FDA or NCI approval. Clinicians do not have the freedom of being able to rapidly adjust trial protocols as they did in the past, which has stifled some of the progress in the field.
One area, however, in which changes should be possible is that of preclinical or 'phase 0' trials that offer a great deal in terms of improving the success rates of later trial stages. 5, 6 After the initial identification of a suitable molecular anticancer target or promising chemotherapeutic drug, the time spent at the preclinical validation stage is critical to ensure that the right molecular entities are taken forward into patients. Unfortunately, this is an area where there are many challenges to overcome, not least the simple fact that the current system financially rewards those who are fastest to market and not necessarily those who are the most careful and diligent in their preclinical assessments. 7 A suggestion to overcome this is to 'stop the clock' on patents to allow the expensive and time-consuming task of careful preclinical assessment and biomarker discovery to be completed, without detriment to the potential financial rewards to be had from a launched product. 7 Unfortunately, this novel suggestion would likely be too open to abuse to be feasible, but the idea is a starting point that might lead to successful changes in regulation.
We also want to discuss patient recruitment to clinical trials. As agents are increasingly developed to target specific markers, it is more likely that patients will require prescreening for biomarkers prior to enrollment in a clinical trial. However, who should pay for the assessment? If this prescreening is not needed by the patient for their standard treatment then it is unlikely to be paid for by their usual health-care provider; but if the assessment is not done, then the patient cannot be recruited to the trialsomething of a Catch-22. In France, an initiative has been set up to perform centralized prescreening of this kind for approved anticancer therapies that are associated with a biomarker. 8 This assessment is intended to allow patients access to the correct targeted anticancer therapy. It is easy to see how an initiative of this type could be expanded to assess patients for eligibility for enrollment in clinical trials; however, that is not part of the focus at present.
A suggestion to improve recruitment is the possibility of the disclosure in the public domain of those centers with a poor recruitment record. 9 The idea that a center's recruitment target, actual accrual and reasons for any disparity should be made public will probably not be popular. However, these data would be informative on several levels. It would be possible to determine if there are trends in recruitment difficulties and if they can be rectified going forward, which in our opinion would be the main benefit of this suggestion. It might also be of interest in terms of trial subgroup analyses and patient location.
Another crucial issue is asking the right trial question and choosing the correct end points for the study. Progression-free survival is a common primary end point and recent investigational therapies often improve this end point by only a few months. Although these gains can be of clinical significance to patients, health-care providers who make assessments based on cost-effectiveness frequently do not approve such agents for use or reimbursement. The result: the intended patient populations do not get access to these expensive, but efficacious, drugs.
2 Perhaps earlier liaison with funding bodies to assess the relative cost-effectiveness of efficacy of these agents in parallel with development might help to avoid this situation, which is destined to increase dramatically in light of the extremely crowded and cost prohibitive drug marketplace.
Close collaboration between industry partners to avoid redundancy in developing multiple agents with the same target would be a considerable step forward, as highlighted by the recent Merck and AstraZeneca collaboration for their respective AKT and MEK inhibitors. Discontinuation of agents earlier in the drug development process that do not meet the criteria suggested by Sharma and Schilsky, 10 would also help to reduce failure rates. As stated earlier, if more recognition was given to rewarding careful and thorough preclinical progress rather than first-to-market drug development, drug companies might also be more willing to work together to invest in preclinical research. Such collaborative efforts might also help validate the robustness of academic research findings. As 50% of published preclinical results are not reproducible by industry, steps to improve such reproducibility with a new public-funded access scheme to leverage academic and industry-reported efforts could help future clinical trial design and limit development of agents with a poor target definition.
Obviously, we have cherry picked just a few examples to discuss here and have not even begun to scratch the surface in terms of what is possible and what has been proposed within the community. It is our hope that this editorial and the articles in this clinical trials focus issue will be illuminating and of interest to our readers, and that possibly they might contribute in a small way to the ongoing changes in clinical trial practice that will benefit researchers, clinicians and patients alike. 
